Infectious Disease Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

The LalelaLung Study: Digital Stethoscope Clinical Evaluation

This study is exploring a new digital stethoscope that uses artificial intelligence to help diagnose pneumonia in young children aged 2 to 59 months. If it works well, doctors could better identify pneumonia and avoid giving antibiotics when they are not needed. This would improve treatment for children and help reduce the problem of antibiotic resistance, especially in places like Cape Town, South Africa, where 350 children are being enrolled.

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

This Phase 3 trial is testing a new vaccine against pneumococcal disease in infants between 2 and 6 months old. The goal is to see if this vaccine is as safe and effective as the current options. If successful, it could offer broader protection against serious infections such as pneumonia and meningitis in young children, and it is recruiting participants in several countries.

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

This trial tested an mRNA vaccine aimed at preventing respiratory syncytial virus (RSV) in both pregnant women and the babies they give birth to. By vaccinating mothers during pregnancy, this approach hopes to protect infants from RSV, a common and sometimes serious infection. The study involved 360 participants in multiple countries and has now completed its enrollment phase.

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

This early-stage study is exploring a new treatment combining a vaccine, antibodies, and pills for adults newly diagnosed with HIV-1 who have started antiretroviral therapy. The aim is to find a way to better control HIV without needing continuous medication. The trial is ongoing with 36 participants in the United States and Brazil.

Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years

This study is testing a new schedule of HPV vaccinations using two different vaccines in girls aged 9 to 14 years. The goal is to improve immune protection against HPV infections, which can lead to serious health problems later on. The trial is active in China with 400 participants, though it is not currently recruiting new volunteers.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.